Slide 1: Business update and 2024 results
PolyPeptide Group AG Business update and 2024 results 11.03.2025 Baar Switzerland 1
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by the Group operates. While the Group believes that such Alternative Financial Performance Measures (APM) PolyPeptide Group AG (“PolyPeptide” or the “Group”). The research and estimates are reasonable and reliable, they, and This P
Slide 3: Agenda
Agenda 1 Business update Juan José González, CEO 2 2024 financial results Marc Augustin, CFO 3 Guidance Juan José González, CEO 4 Q&A All 3
Slide 4: Q&A
Q&A The presentation will be followed by a Q&A session. Anyone who wishes to ask a question, or make a comment can do it in the following ways: • Through the telephone by pressing * and 1 (please register on the website to receive the personal dial-in details) In case of assistance please press * an
Slide 5: Substantial improvements in profitability and cash flow. Positioned for strong growth
Substantial improvements in profitability and cash flow. Positioned for strong growth Strong commercial revenue growth, driven by increased demand and approval of phase III projects; metabolic business more than doubled over the last three years Substantial improvement in profitability – EBITDA marg
Slide 6: Peptides – one of the most attractive market for CDMO's
Peptides – one of the most attractive market for CDMO’s Global therapeutic peptide market potential Peptide drugs in clinical development (Phase I to III)2 (USD bn)1 Total 321, split by therapeutical area in % Metabolic CAGR: >10% ~130 Oncology 27% 23% Neurology Cardiovascular Infectious diseases Ot
Slide 7: The GLP-1 / metabolic opportunity has increased
The GLP-1 / metabolic opportunity has increased Obesity co-morbidities Strong performance of top New entrants are advancing next significantly expand market players generation molecules Major depressive disorder Alzheimer’s disease Ongoing success of blockbuster drugs Obstructive sleep apnea Substan
Slide 8: PolyPeptide's superior customer proximity and deep peptide expertise
PolyPeptide’s superior customer proximity and deep peptide expertise 454 152 381 • A leader in the peptide Braine-l’Alleud Strasbourg Malmö CDMO market with over 70 years of experience • Strong track record of Baar, Switzerland (Headquarter) 11 over 1,000 therapeutic peptides manufactured • Global c
Slide 9: Growth strategy anchored on innovation
Growth strategy anchored on innovation Vision Most innovative peptide CDMO Competitive Innovation Development Modularity Advantages Multi-site network Operational/quality Talent, culture, Foundation Industrial-scale capabilities excellence and ESG 9
Slide 10: Rich development pipeline and exposure to metabolic driving growth
Rich development pipeline and exposure to metabolic driving growth Active Custom Development Projects Revenue by Therapeutic Area (EUR m) CAGR1 201 336.8 15.4% 196 282.1 147.2 8.1% Covid 63.2 Other 169 166 Other 116.5 56.2 11.9% Oncology 40.2 133.4 28.9% Phase III 30 32 Metabolic 62.2 2021 2024 2021
Slide 11: Business mix shifting to commercial revenue with large pharma
Business mix shifting to commercial revenue with large pharma Revenue by Business Area Revenue by Customer Type (EUR m) (EUR m) CAGR1 CAGR1 336.8 15.4% 336.8 15.4% 39.3 6.2% 282.1 282.1 118.1 4.4% Covid 63.2 Covid 63.2 92.0 11.3% Other 32.8 Development 103.8 Biotech 66.7 218.6 23.8% 205.5 19.8% Larg
Slide 12: Capacity expansion plan on track to meet 2028 outlook
Capacity expansion plan on track to meet 2028 outlook Today 2021 2024 2028 2024 update Maintenance (across sites) • Ensuring maintenance of manufacturing infrastructure across sites • Finalized debottlenecking of capacity in Torrance with progressive benefits coming through Debottlenecking • Planned
Slide 13: Building new capabilities and targeted hiring to execute our strategy
Building new capabilities and targeted hiring to execute our strategy • Research on resin formulations Nomination Board of Directors Further deepening 1 • PFAS-free SPPS alternatives peptides expertise • Numerous scientific publications Jo LeCouilliard Independent member; Financial background; • Pro
Slide 14: Agenda
Agenda 1 Business update Juan José González, CEO 2 2024 financial results Marc Augustin, CFO 3 Guidance Juan José González, CEO 4 Q&A All 14
Slide 15: FY2024 revenue growth driven by commercial business
FY2024 revenue growth driven by commercial business Revenue, EURm (% YOY Growth) +16.4 (+5.1%) 336.8 320.4 52.7 36.3 • Trend reflecting demand for drugs across therapeutical areas and regulatory approval of phase III projects Incl. EUR 5.8m Covid revenue • Accelerated growth in H2 vs strong previous
Slide 16: Substantial progress in restoring profitability
Substantial progress in restoring profitability EBITDA, EURm (% margin) +9.4ppts -1.9% 7.5% +31.4 9.5 25.4 • EBITDA margin +9.4ppts, from -1.9% to 7.5% • EUR 31.3m improvement, driven by operational 31.3 performance and changes in product mix • Higher personnel expenses with average FTEs up 7.4% vs.
Slide 17: Result for the period reflects operational improvement
Result for the period reflects operational improvement Summary P&L EUR m 2023 2024 Delta Revenue 320.4 336.8 16.4 EBITDA -6.0 25.4 31.3 margin % -1.9 7.5 9.4 Depreciation, amortization & impairment -30.5 -32.7 -2.2 Operating result (EBIT) -36.5 -7.4 29.1 Financial Income 0.1 6.8 6.7 Financial Expens
Slide 18: Improved operating cash flow and increased investments in capacity
Improved operating cash flow and increased investments in capacity Net Change in Cash, EUR m Operating cash flow 72.5 91.0 • Period-end cash and cash equivalents before repayment of debt on par with prior year 95.7 16.9 94.1 • Higher operating cash flow driven by improved 25.8 profitability 68.3 • I
Slide 19: Multi-layered financing strategy for growth
Multi-layered financing strategy for growth Mid-term outlook: “Ensuring capacity also beyond 2028” 1 Improve profitability and cash flow 2 Customer funding support 3 Utilization of credit facilities Expansion of credit facilities (ongoing discussions) and extension of unsecured short-term credit fac
Slide 20: Agenda
Agenda 1 Business update Juan José González, CEO 2 2024 financial results Marc Augustin, CFO 3 Guidance Juan José González, CEO 4 Q&A All 20
Slide 21: 2028 Outlook reconfirmed with healthy evolution targeted for 2025
2028 Outlook reconfirmed with healthy evolution targeted for 2025 2023A 2024A 2025 Guidance 2028 Outlook Revenue 10% to 20% EUR m 320 337 Double 2023 revenue growth vs. 2024 EBITDA -1.9% 7.5% Increasing vs. 2024 Approaching 25% Margin CAPEX 17.1% 26.1% ~20% 15% to 20% (in % of Revenue) 21
Slide 22: Agenda
Agenda 1 Business update Juan José González, CEO 2 2024 financial results Marc Augustin, CFO 3 Guidance Juan José González, CEO 4 Q&A All 22
Slide 23: Q&A
Q&A The presentation will be followed by a Q&A session. Anyone who wishes to ask a question, or make a comment can do it in the following ways: • Through the telephone by pressing * and 1 (please register on the website to receive the personal dial-in details) In case of assistance please press * an
Slide 24: Appendix
Appendix PolyPeptide Group AG polypeptide.com 24
Slide 25: Consolidated income statement
Consolidated income statement 1 January – 31 December 25
Slide 26: Consolidated statement of financial position
Consolidated statement of financial position As at 31 December 26
Slide 27: Consolidated statement cash flow
Consolidated statement cash flow 1 January – 31 December 27
Slide 28: Contact and calendar
Contact and calendar Contact Events 2025 Michael Stäheli 12 March 2025 Roadshow Zurich with ZKB Head of Investor Relations & Corporate Communications 13 March 2025 Roadshow London with UBS T: +41 43 502 0580 E: michael.staeheli@polypeptide.com 17 March 2025 Roadshow New York with MS 9 April 2025 AGM
Slide 29: Thank you
Thank you PolyPeptide Group AG polypeptide.com
Slide 30: *|% PolyPeptide
*|% PolyPeptide